| Literature DB >> 35693968 |
Yiwei Gu1,2, ChangJing Wu1, Feng Qin1, Jiuhong Yuan1,2.
Abstract
Erectile dysfunction (ED) is a disease with a wide scope of etiologies. Obstructive sleep apnea (OSA) is considered one of the risk factors for ED and is less studied. A growing lot of evidence show an association between OSA and ED. This study provides an updated review of the relationship between ED and OSA and the possible physiological mechanisms of ED in patients with OSA based on the current evidence. In clinical interviews, patients with ED may benefit from a sleep evaluation. However, further clinical investigations and more basic research are needed to illustrate the relationship between ED and OSA.Entities:
Keywords: ED; obstructive sleep apnea (OSA); physiopathological mechanism; prevalence; relationship
Year: 2022 PMID: 35693968 PMCID: PMC9178074 DOI: 10.3389/fpsyt.2022.766639
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 5.435
The characteristics of the included clinical studies.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Schiavi et al. ( | Cross-sectional | 70 | 45–75 | NPT psychosexual interview | Partial PSG (AHI ≥ 5) |
| Heruti et al. ( | Cross-sectional | 3,363 | 36.1 ± 6.8 | SHIM Questionnaire | SQQ |
| Hanak et al. ( | Cohort | 827 | 64 (51-90) | Brief Male Sexual | Questionnaire (self-reported) |
| Andersen et al. ( | Cross-sectional | 467 | 20–80 | Questionnaire | PSG |
| Szymanski et al. ( | Cross-sectional | 90 | Non-OSA: 54.5 ± 8.3 | IIEF-5 | Berlin Questionnaire |
| Chen et al. ( | Cross-sectional | 60,326 | 46.4 ± 13.1 | Ambulatory claim database | ICD-9-CM PSG |
| Chen et al. ( | Cross-sectional | 53,335 | Non-OSA: 53.8 ± 16.6 | ICD-9-CM | ICD-9-CM |
| Chung et al. ( | Cross-sectional | 6,180 | 47.8 ± 13 | ICD-9-CM | ICD-9-CM PSG |
| Bozorgmehri et al. ( | Cohort | 2,857 | 76.2 ± 5.5 | IIEF-5 | PSG |
| Pressman et al. ( | Cross- sectional | 31 | 58.4 ± 6.8 | NPT | PSG |
| Hirshkowitz et al. ( | Case–control | 275 | 50 ± 9.0– 58 ± 9.8 | NPT | PSG |
| Hirshkowitz et al. ( | Cross- sectional | 1,025 | 54 (20-82) | NPT | PSG |
| Chediak et al. ( | Cross- sectional | 37 | 52.2 ± 14 | NPT | PSG |
| Seftel et al. ( | Cross- sectional | 285 | 53 ± 13 (16-81) | Medical History | Cleveland Sleep Habits Questionnaire |
| Fanfulla et al. ( | Case–control | 50 | 48 ± 11.9 | Self-reported | PSG |
| Margel et al. ( | Cross-sectional | 209 | AHI <5: 43.95 ± 11.8; | IIEF-5 | PSG |
| Teloken et al. ( | Cross-sectional | 50 | 48 ± 10 | IIEF-5 | ESS > 10 |
| Shin et al. ( | Case–control | 59 | Control: 42.9 ± 9.9; | KIIEF-5 | PSG SAQLI ESS |
| Budweiser et al. ( | Cross-sectional | 401 | ED: 61.7 (53.7–69.6); | IIEF-15 | PSG |
| Stannek et al. ( | Case–control | 186 | Control: 46.6 ± 13.7; | Modified IIEF | PSG |
| Petersen et al. ( | Case–control | 1,493 | 50.6 ± 10.3 (30-69) | Fugl-Meyer | PSG |
| Gurbuz et al. ( | Case–control | 39 | Control: 42.3 ± 7.9; | IIEF-5 | PSG |
| Santos et al. ( | Cross-sectional | 62 | 52.16 | IIEF-5 | Polygraphic cardiorespiratory sleep study |
| Bouloukaki et al. ( | Cross-sectional | 404 | 42.6 ± 9.3 (18-65) | IIEF-5 | PSG |
| Jeon et al. ( | Cross-sectional | 713 | 44.8 ± 12.4 | KIIEF-5 | PSG |
| Popp et al. ( | Cross-sectional | 381 | ED: 60.7 ± 11.2; | IIEF-15 | PSG |
| Taken et al. ( | Case–control | 55 | 43.09 ± 11.48 | IIEF-15 | PSG |
| Pascual et al. ( | Clinical trials | 150 | ED:48.7(1); | IIEF-15 | PSG |
| Schulz et al. ( | Clinical trials | 94 | 51.5 ± 0.9 | IIEF-5 | PSG |
PSG, polysomnography; IIEF, The International Index of Erectile Function; ESS, Epworth Sleepiness Scale; SAQLI, Calgary Sleep Apnea Quality of Life Index; VIGIL-S1 test, Vigil-vigilance; KIIEF, Korean version of the IIEF; NPT, nocturnal penile tumescence; SQQ, Sleep Quality Questionnaire; SHIM, Sexual Health Inventory for Men; ICD-9-CM, The International Classification of Diseases, Ninth Revision, Clinical Modification.
The characteristics of the included basic science studies.
|
|
|
|
|
|
|---|---|---|---|---|
| Soukhova-O'Hare et al. ( | CIH mice | 5 or 24 weeks | Tadalafil | Sexual activity was suppressed after CIH. |
| Liu et al. ( | LTIH rats | 6 weeks | Apocynin | LTIH markedly attenuated the erectile responses, and these effects were partially prevented by apocynin treatment |
| Zhu et al. ( | CIH rats | 5 weeks | N-acetylcysteine (NAC) | Administration of NAC before CIH significantly improved CIH-induced impaired erectile function |
| Liang et al. ( | CIH rats | 8 weeks | miR-301a-3p-enriched exosome | miR-301a-3p-enriched exosome treatment significantly recovered erectile function |
CIH, Chronic intermittent hypoxia; LTIH, Long-term intermittent hypoxia.